Article and Video CATEGORIES
The current standard of care for SCLC shows limited results with high toxicities. Drs. Soria, Gandhi, and West discuss new ASCO 2015 data that show promise for a subset of patients with PD-L1 expression on Keytruda (pembrolizumab) or Opdivo (nivolumab).
[powerpress]
Please feel free to offer comments and raise questions in our Discussion Forums.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
I hope you find some help through your doc or PT.
Take care,
Janine
Hi Revtoby, Welcome to Grace. I'm sorry you and your wife are worried about cancer but we couldn't say whether or not your wife's leison is cancer no matter how much...
Canyil, I'm sorry your father and you are going through this. While we can't give urgent help we are her to help offer info and resources to help make the best...
Hi ramosking, Welcome to Grace. I'm sorry you're suffering. It doesn't sound like you have a pancoast tumor. It does seem like you should see your PCP or a pulmonologist for...